# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-18-003091
Filing Date
2018-03-16
Accepted
2018-03-16 17:06:33
Documents
67
Period of Report
2017-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | f10k2017_actiniumpharma.htm | 10-K | 1386838
2 | SIXTH AMENDMENT TO THE 2013 AMENDED AND RESTATED STOCK PLAN, AS AMENDED | f10k2017ex10-56_actinium.htm | EX-10.56 | 6049
3 | OFFER LETTER, EFFECTIVE JANUARY 2, 2018, BETWEEN DALE L. LUDWIG AND ACTINIUM PHA | f10k2017ex10-57_actinium.htm | EX-10.57 | 25225
4 | INDEMNIFICATION AGREEMENT, DATED JANUARY 5, 2018, BETWEEN DALE L. LUDWIG AND ACT | f10k2017ex10-58_actinium.htm | EX-10.58 | 72591
5 | OFFER LETTER, EFFECTIVE JANUARY 31, 2018, BETWEEN ANIL KAPUR AND ACTINIUM PHARMA | f10k2017ex10-59_actinium.htm | EX-10.59 | 25654
6 | INDEMNIFICATION AGREEMENT, DATED FEBRUARY 8, 2018, BETWEEN ANIL KAPUR AND ACTINI | f10k2017ex10-60_actinium.htm | EX-10.60 | 77473
7 | CONSENT OF GBH CPAS, PC | f10k2017ex23-1_actinium.htm | EX-23.1 | 1988
8 | CERTIFICATION | f10k2017ex31-1_actinium.htm | EX-31.1 | 10459
9 | CERTIFICATION | f10k2017ex31-2_actinium.htm | EX-31.2 | 10300
10 | CERTIFICATION | f10k2017ex32-1_actinium.htm | EX-32.1 | 3202
11 | CERTIFICATION | f10k2017ex32-2_actinium.htm | EX-32.2 | 3274
12 | GRAPHIC | image_003.jpg | GRAPHIC | 148755
13 | GRAPHIC | image_001.jpg | GRAPHIC | 18556
| Complete submission text file | 0001213900-18-003091.txt |  | 5064475

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
14 | XBRL INSTANCE FILE | atnm-20171231.xml | EX-101.INS | 692492
15 | XBRL SCHEMA FILE | atnm-20171231.xsd | EX-101.SCH | 43677
16 | XBRL CALCULATION FILE | atnm-20171231_cal.xml | EX-101.CAL | 42639
17 | XBRL DEFINITION FILE | atnm-20171231_def.xml | EX-101.DEF | 186518
18 | XBRL LABEL FILE | atnm-20171231_lab.xml | EX-101.LAB | 332385
19 | XBRL PRESENTATION FILE | atnm-20171231_pre.xml | EX-101.PRE | 274811

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36374 | Film No.: 18696529
SIC: 2834 Pharmaceutical Preparations